Mark R Fielden
Affiliation: Amgen Inc
- Development and evaluation of a genomic signature for the prediction and mechanistic assessment of nongenotoxic hepatocarcinogens in the ratMark R Fielden
Comparative Biology and Safety Sciences, Amgen, South San Francisco, California 94080, USA
Toxicol Sci 124:54-74. 2011..These results support a potential early preclinical testing paradigm to catalyze broader understanding of putative NGHCs...